Mizuho initiated coverage of Henry Schein (HSIC) with a Neutral rating and $75 price target While the firm believes that Henry Schein remains the leading global dental and medical distribution company, it notes that the company has been challenged to grow organic sales over the past two years due to “a combination of economically soft end-markets,” and “an unexpected cyber-attack on the company in September 2023.” The firm has a cautious view for 2025 that is corroborated by the Mizuho dental survey, which suggests the challenging industry trends seen in 2024 are “unlikely to improve in 2025.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HSIC:
- Henry Schein to acquire Acentus, terms not disclosed
- Ananym urges Henry Schein to cut spending, sell unit, Reuters reports
- Henry Schein management to meet with Piper Sandler
- Early notable gainers among liquid option names on November 18th
- Henry Schein participates in a conference call with JPMorgan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
